It joins an antibody to peptides so that it lasts for weeks, and it acts in two opposite ways: it activates the GLP-1 receptor and blocks the GIP receptor. In a 52-week phase 2 trial, given every 4 or 8 weeks, it lowered weight by 12.3% to 16.2% in people with obesity, against 2.5% on placebo.1 We found no label for it on DailyMed on November 20, 2026.2
What it is
The trial report describes maridebart cafraglutide as a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism, intended for obesity.1 Two things set it apart from the approved medicines.
- The GIP receptor is blocked, not activated. Tirzepatide activates both receptors. A 2025 review written by Eli Lilly scientists notes the competing idea that blocking the GIP receptor could also help with weight, because GIP may help fat tissue store fat, and argues the other side.3 MariTide is the test of the blocking approach.
- It is given monthly or less often. The antibody part keeps it in the body long enough for an injection every 4 weeks, or every 8 weeks in one group, against weekly for semaglutide and tirzepatide.1
The phase 2 trial
The trial enrolled 592 adults in two groups and followed them for 52 weeks. Doses of 140, 280 or 420 mg were given every 4 weeks, or 420 mg every 8 weeks. In the obesity group, some people started at the full dose and others climbed to 420 mg over 4 or 12 weeks; in the diabetes group, everyone started at the full dose. The main result was the change in weight at week 52.1 Testing so many schedules is typical of a phase 2 trial, whose job is to find which dose and pace to carry into larger trials.
- Obesity without diabetes: 465 people, 63% women, average age 47.9 and body mass index 37.9. Weight fell by 12.3% to 16.2% across the dose groups, against 2.5% on placebo.
- Obesity with type 2 diabetes: 127 people, 42% women, average age 55.1 and body mass index 36.5. Weight fell by 8.4% to 12.3%, against 1.7% on placebo, and HbA1c fell by 1.2 to 1.6 points, against a rise of 0.1.
These figures count everyone as assigned, regardless of whether they kept taking the drug. The trial was funded by Amgen.1
Side effects
Stomach and gut events were common, but less frequent when the dose was raised in steps and started lower; the report found no unexpected safety signals.1 That fits the experience with the approved medicines, whose labels raise the dose in steps to reduce the same side effects.4 Our page on nausea on a GLP-1 covers what helps.
What is still open
A phase 2 trial cannot answer the questions that decide whether a drug reaches patients: how it performs over longer periods and in larger groups, and whether blocking the GIP receptor is safe for years. Those are the jobs of phase 3 trials. Until their results and a U.S. label exist, MariTide is a trial medicine.2
Next to the approved medicines
The phase 2 results are lower than in the label trials of Zepbound, where 15 mg lowered weight by 20.9% over 72 weeks, and close to Wegovy 2.4 mg at 14.9% over 68 weeks.5 The trials differ in length, people and dosing, and phase 2 trials are designed to choose doses, not to settle how a drug compares. The appeal of MariTide lies as much in the schedule as in the size of the effect: an injection every 4 weeks means 13 a year, and every 8 weeks about 7, against 52 for a weekly medicine. Our page on timing a weekly GLP-1 shot shows what a weekly schedule involves.
Sources
- Jastreboff AM, Ryan DH, Bays HE, et al. Once-monthly maridebart cafraglutide for the treatment of obesity: a phase 2 trial. N Engl J Med 2025;393:843-857. Funded by Amgen. doi:10.1056/NEJMoa2504214
- DailyMed, U.S. National Library of Medicine. Search for "maridebart", no results; read November 20, 2026. dailymed.nlm.nih.gov
- Samms RJ, Sloop KW. A contemporary rationale for agonism of the GIP receptor in the treatment of obesity. Diabetes 2025;74:1326-1333. Both authors are employees of Eli Lilly and Company. doi:10.2337/dbi24-0026
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2 and 6.1. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026, section 14; and ZEPBOUND prescribing information, section 14. U.S. Food and Drug Administration. accessdata.fda.gov
Related analyses
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Wegovy weight loss chart: the trial results week by week, in your own weight
When to take your GLP-1 shot: time of day, changing the day and time zones
Log any GLP-1 medicine you take and see your doses, weight and symptoms together.
Open Dose Insider